Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)

Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)

TA295

Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)

Technology appraisals TA295 Issued: August 2013

• Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy

  Technology appraisals, TA295 - Issued: August 2013 What has NICE said?
  NICE does not recommend everolimus, given with another drug called exemestane, for postmenopausal women with advanced breast cancer that is HER2 negative and hormone-receptor positive, and that has recurred or worsened after treatment with a non-steroidal aromatase inhibitor (another type of anticancer drug).
  Why has NICE said this?
  NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE did not recommend everolimus because it does not provide enough benefit to patients to justify its high cost, and did not qualify for special consideration.
  

  • Other information

    How this guidance was produced

    Background information

    • TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor): press release
  This page was last updated: 05 September 2013